Myovant Sciences to Present at Upcoming December Investor Conferences

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) has announced participation in two upcoming investor conferences. On December 1, 2020, executives will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference at 4:45 p.m. Eastern time, followed by virtual one-on-one meetings. Also, Dr. Lynn Seely will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference with a pre-recorded presentation available at 10 a.m. Eastern time. These presentations can be accessed on Myovant's Investors & Media website section.

BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:

• Evercore ISI 3^rd Annual HealthCONx Virtual Conference on December 1, 2020 at 4:45 p.m. Eastern time. Lynn Seely, M.D., chief executive officer of Myovant Sciences, Inc., and Frank Karbe, president and chief financial officer of Myovant Sciences, Inc., will participate in a webcast presentation. Management will also participate in virtual one-on-one investor meetings on December 1.
  
  
• Piper Sandler 32^nd Annual Virtual Healthcare Conference. A pre-recorded presentation by Dr. Seely will be available at 10 a.m. Eastern time today on the investor relations page of Myovant’s website, investors.myovant.com. Management will participate in virtual one-on-one investor meetings on December 3, 2020.
  

The presentations will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

About Myovant Sciences
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
investors@myovant.com

Media Contact:
Albert Liao
Director, Corporate Communications
Myovant Sciences, Inc.
media@myovant.com

FAQ

What investor conferences will Myovant Sciences participate in December 2020?

Myovant Sciences will participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 1, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference.

What time is Myovant Sciences' presentation at the HealthCONx Virtual Conference?

Myovant Sciences' presentation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference is scheduled for December 1, 2020, at 4:45 p.m. Eastern time.

Where can I find the presentation from Myovant Sciences' Piper Sandler Healthcare Conference?

The pre-recorded presentation by Dr. Lynn Seely at the Piper Sandler 32nd Annual Virtual Healthcare Conference can be accessed on Myovant's investor relations page.

When will virtual one-on-one meetings with Myovant Sciences management take place?

Virtual one-on-one investor meetings with Myovant Sciences management are scheduled for December 1 and December 3, 2020.

What is Myovant Sciences focusing on in their healthcare approach?

Myovant Sciences aims to redefine care for women and men through innovative science and advocacy, focusing on treatments like relugolix for advanced prostate cancer and uterine fibroids.